Business
electroCore Expands Intellectual Patent Portfolio for nVNS Technology
ROCKAWAY, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today
About this update from Electrocore, Inc.
[{"type":"text","content":"ROCKAWAY, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents and intends to issue a third new patent related to its non-invasive vagus nerve stimulation (nVNS) technology to electroCore, including the following patents: U.S. Patent No. 11,534,600 entitled “Non-Invasive Nerve Stimulation to Treat or Prevent Autism Spectrum Disorders and Other Disorders of Psychological Development” issued on December 27, 2022. This patent is generally related to devices and methods for treating behavioral disorders, such as attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder and Asperger syndrome with nVNS by applying an electrical impulse having bursts of 2-20 pulses and a frequency of 1 to 100 Hz.U.S. Patent No. 11,581,090 entitled “Technologies for Initial Provisioning and Refilling of Medical Devices” issued on February 14, 2023. This patent is generally related to electrical stimulation devices that limit the use of the devices to a prescribed number of treatments (e.g., doses) and/or a prescribed time period.U.S. Patent No. 11,590,341 entitled “Vagal Nerve Stimulation Therapy” to be issued on February 28, 2023. This patent is generally related to a method of treating post-operative symptoms in a patient that includes attaching a patch to the neck of the patient and wirelessly transmitting electrical impulses to electrodes in the patch to reduce intraperitoneal or retroperitoneal inflammation. The electrical impulses are applied for at least two doses/per day with each dose having a duration of 60 seconds to 5 minutes. “We are excited to broaden our intellectual property with the addition of these new patents” stated Dan Goldberger, Chief Executive Officer of electroCore. “electroCore’s proven technology and expanding intellectual property highlights its use across a range of disorders and diseases. We are excited to begin exploring the behavioral disorder space and the potential for nVNS in a post-operative setting.” About electroCore, Inc. electroCore, Inc. is a commercial stage bioelectronic company dedicated to improving outcomes through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercial...